– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback